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Abstract
Background: Recent reports indicate that microRNAs (miRNAs) play a critical role in malignancies. However, the
role that miRNAs play in pancreatic cancer remains to be determined. The purpose of this study was to investigate
aberrantly expressed miRNAs in pancreatic cancer tissues and demonstrate their roles in disease progression.
Results: We detected the expression patterns of miRNAs in 10 pancreatic cancer tissues and their adjacent benign
tissues by quantitative real time-PCR (qRT-PCR) and found that miR-15a and miR-214 were dysregulated in the
tumor samples. This is the first time that miR-214 has been identified as aberrantly expressed in pancreatic cancer.
In vitro experiments showed that overexpression of miR-15a inhibited the viability of pancreatic cancer cells,
whereas overexpression of miR-214 decreased the sensitivity of the cells to gemcitabine (GEM). Furthermore, we
identified WNT3A and FGF7 as potential targets of miR-15a and ING4 as a target of miR-214.
Conclusions: Aberrant expression of miRNAs such as miR-15a and miR-214 results in different cellular effects in
pancreatic cancer. Downregulation of miR-15a might contribute to proliferation of pancreatic cancer cells, whereas
upregulation of miR-214 in pancreatic cancer specimens might be related to the poor response of pancreatic
cancer cells to chemotherapy. MiR-15a directly targets multiple genes relevant in pancreatic cancer, suggesting that
it may serve as a novel therapeutic target for treatment of the disease.
Background
Pancreatic cancer is a disease with a high rate of mortal-
ity. It is generally diagnosed at an advanced stage, at
which point no successful therapies are available. Pan-
creatic cancer is characterized by the potential for local
invasion, enabling it to spread during early developmen-
tal stages of the disease. Even when diagnosed early, the
limited response of pancreatic cancer to available treat-
ments, including surgical resection and chemotherapeu-
tics, contributes to its high mortality rate [1,2].
Therefore, there is an urgent need to discover novel
early diagnostic biomarkers and to identify new thera-
peutic strategies. However, the molecular mechanisms
underlying the high tumorigenicity of pancreatic cancer
are not well known.
Recently, a new family of small regulatory RNAs called
microRNAs (miRNAs) was discovered, and their roles in
many biological processes are under investigation. MiR-
NAs are short (approximately 22 nt in length) noncod-
ing RNAs that regulate gene expression [3] and have
been implicated in the regulation of cancer progression
[4-6]. By negatively regulating tumor suppressor genes
or oncogenes, miRNAs can play a role in promoting
cancer [5].
Unlike most currently available biomarkers, miRNA
expression appears to be cell type- and disease-specific
and can be used for the classification of certain cancer
histotypes [7,8]. Various miRNAs are aberrantly
expressed in pancreatic cancer, and these aberrant
expression patterns can accurately differentiate pancrea-
tic cancer from benign pancreatic tissues [9-12]. Lee
et al. also identified several miRNAs aberrantly
expressed in pancreatic ductal adenocarcinoma (PDAC),
which suggests that these novel molecules could serve
as diagnostic biomarkers for the disease [13]. However,
the association between miRNAs and their roles in pan-
creatic cancer progression remains to be elucidated.
In this study, we demonstrated that miR-15a and miR-
214 were significantly dysregulated in pancreatic cancer
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the cancer samples relative to the benign tissues sam-
ples, whereas miR-214 was upregulated. In pancreatic
cancer, miR-15a directly regulates WNT3A and FGF7,
and miR-214 might regulate ING4. In addition, we
found that overexpression of miR-15a could reduce the
viability of pancreatic cancer cells, whereas miR-214
counteracted the pro-apoptotic effect of gemcitabine
(GEM) in BxCP-3 cells.
Results and discussion
MiR-15a downregulation and miR-214 upregulation in
human pancreatic cancer
To identify dysregulated miRNAs, we used qRT-PCR to
measure the expression of seven mature miRNAs (miR-
15a, miR-27a, miR-100, miR-125b, miR-181a, miR-200a
and miR-214) in 10 pancreatic cancer tissues and their
adjacent benign tissues. These seven mature miRNAs
were chosen based on recent reports that identified
them as having important functions in cancers. After
normalization to U6 RNA expression as a control, the
differential expression patterns of the miRNAs in cancer
and benign pancreatic tissues were determined.
Among the miRNAs studied, we found that four miR-
NAs were frequently overexpressed in the cancer tissues
studied: miR-100, miR-125b, miR-200a and miR-214
(Table 1 and Figure 1A). In particular, miR-214 expres-
sion was elevated in 8 of 10 (80%) cancer specimens.
Only one miRNA, miR-15a, showed decreased expres-
sion in cancer tissues compared with matched benign
pancreatic tissues; this effect was evident in 7 of 10
(70%) samples (Figure 1B).
Among the four upregulated miRNAs, miR-214 was
previously reported to be associated with mouse pan-
creas development [14]. However, there are no reports
on the function of miR-214 in human pancreas
development or in the chemoresistance of pancreatic
cancer. This is the first report implicating the dysregula-
tion of miR-214 in pancreatic cancer. As for miR-15a, a
tumor suppressor that has been reported in various can-
cers, its functions in pancreatic cancer are unknown;
however, it was the only one downregulated in our
examination. Therefore, miR-214 and miR-15a were
chosen for further study.
MiR-15a overexpression reduces cell viability, whereas
miR-214 decreases sensitivity to GEM in pancreatic cancer
cells
To investigate the potentialf u n c t i o n so fm i R - 1 5 aa n d
miR-214 in pancreatic cancer, we first measured the via-
bility of cells transfected with miR-15a/miR-214 mimics
or their controls (mimics-NC) using the CCK-8 assay.
BxCP-3 pancreatic cells were used in our examination.
The transfection efficiency of both miR-15a and miR-
214 and their corresponding controls in BxCP-3 cells
was measured by qRT-PCR assay. The results were ana-
lyzed using the paired Student’s t-test. MiR-214 was
upregulated more than 14-fold in BxCP-3 cells after
transfection, whereas miR-15a was upregulated about
6-fold (Figure 2A); this result indicated better transfec-
tion efficiency of miR-214. We then assessed cell viabi-
lity. The CCK-8 assay showed that overexpression of
miR-15a significantly decreased the viability of BxCP-3
cells compared with the control (p < 0.05) (Figure 2B).
These results indicate that the expression level of miR-
15a is important for pancreatic cancer cell growth.
Because miR-15a was downregulated in pancreatic can-
cer, we hypothesized that miR-15a might function as a
tumor suppressor in the disease, a role it has been
shown to play in other cancers [15-18].
Documented evidence indicates that miR-214 func-
t i o n sa se i t h e ra no n c o g e n eo rat u m o rs u p p r e s s o ri n
different cancers. It was also reported that miR-214
negatively regulates HeLa cell proliferation and increases
the ability of T cells’ viability [19,20]. However, we
observed no obvious effect of miR-214 overexpression
on cell viability (p > 0.05) (Figure 2B), which implies
that miR-214 might have other roles in pancreatic can-
cer. A previous study showed that miR-214 can promote
cell survival and cisplatin resistance in human ovarian
cancer [21]. Because overexpression of miR-214 was
observed in pancreatic cancer tissues, we questioned
whether this phenomenon might be related to tumor
cell survival and drug resistance in pancreatic cancer.
T oa d d r e s st h i si s s u e ,w ei n v estigated the expression
patterns of miR-214 in BxCP-3 cells treated with GEM.
GEM is currently the first-line treatment for advanced
pancreatic cancer, and it acts by inhibiting tumor cell
proliferation and inducing apoptosis [22-25]. Prior to
determining the effects of GEM on miR-214, we
Table 1 Expression of miRNAs in pancreatic cancer
specimens compared with adjacent benign pancreatic
tissues









qRT-PCR was used to measure expression of seven miRNAs in 10 pancreatic
cancer tissues and their adjacent benign pancreatic tissues. MiRNA expression
levels are represented as relative values, compared to those of adjacent
benign pancreatic tissues, which were taken as 1. Median value was
calculated to indicate the frequency of a miRNA expression downregulated or
upregulated in pancreatic cancer.
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Page 2 of 9examined the effect of GEM on cell viability at 24, 48
and 72 hrs using the CCK-8 assay. Cell viability
decreased in a time-dependent manner in response to
GEM treatment (Figure 2C). After 72 hrs of 10 μM
GEM treatment, cell viability decreased to approximately
20% compared with untreated cells. Next, we detected
the expression pattern of miR-214 in cells treated with
GEM. We found that miR-214 was dramatically downre-
gulated after treatment with GEM. MiR-214 levels
decreased by 60% at 24 hrs and remained low for 72 hrs
(Figure 2D), indicating that miR-214 was responding to
the drug treatment. We then investigated whether over-
expression of miR-214 could modulate the sensitivity of
BxCP-3 cells to GEM-induced apoptosis. After 72 hrs of
GEM treatment, we found that the viability of BxCP-3
cells transfected with miR-214 mimics was significantly
higher (about 22%) than that of the NC and MOCK
negative control groups (Figure 2E). These results sug-
gest that miR-214 might be involved in the chemoresis-
tance of pancreatic cancer cells.
Figure 1 Expression patterns of miR-15a and miR-214. qRT-PCR was performed to detect (A) miR-214 and (B) miR-15a expression in 10
pancreatic cancer tissues and their adjacent benign pancreatic tissues. Expression levels of miRNAs in adjacent benign pancreatic tissues were
set as 1. Relative values were calculated to indicate the frequency of miRNA expression downregulated or upregulated in pancreatic cancer.
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and FGF7, and miR-214 potentially downregulates ING4
to inhibit apoptosis induced by GEM
To further study the mechanisms of both miR-15a and
miR-214 in pancreatic cancer cells, we predicted and
validated potential targets for both miRNAs. Putative
t a r g e tg e n e st h a tw e r ei d e n t i f i e db yo n eo rm o r eo ff i v e
different target prediction algorithms (PicTar, Target-
Boost, TargetScanS, MiRanda and miRbase) were
screened for the location and number of putative bind-
ing sites as well as their biologic relevance. Among the
candidate targets of miR-15a chosen for experimental
validation were PIM1, CDC25A, BCL2L2, WNT3A,
SMAD7, LRP6 and FGF7, each of which has been
reported to play a role in cell proliferation (Table 2).
Using the same methods, seven candidates: RASSF5,
PIM1, BAX, BIK, NEO1, ACVR1B and ING4, were pre-
dicted as the putative targets of miR-214 and chosen for
experimental validation (Table 3). The wild-type 3’-UTR
of each gene was cloned into the 3’-UTR of a Renilla
luciferase reporter gene of a modified psiCHECK2
expression vector, and the resultant constructs were
transfected into 293T cells using Lipofectamine 2000.
Luciferase expression in cells expressing the WNT3A
and FGF7 reporters was significantly suppressed (18%
and 20%, respectively) when co-transfected with miR-
15a mimics (Figure 3A and 3C). These data indicate
that WNT3A and FGF7 might be targets of miR-15a. In
addition, miR-214 repressed the luciferase activity of the
ING4 reporter construct by 13% (Figure 3B and 3C).
Expression levels of the remaining reporter constructs
were unaffected by miRNA co-transfection.
WNT3A is a member of the Wnt/b-catenin signaling
pathway. Dysregulated Wnt/b-catenin signaling has been
linked to various human diseases, including cancer.
WNT3A promotes the activation of survival and
Figure 2 MiR-15a and miR-214 have different roles in pancreatic cancer cells. (A) qRT-PCR was used to investigate miRNA transfection
efficiency. Both miR-15a and miR-214 were significantly increased compared to their mimics-NC (control) in BxCP-3 cells. (B) The viability of
BxCP-3 cells after transfection was measured by CCK-8 assay. (C) Cell viability was measured using the CCK-8 assay in BxCP-3 cells treated with
10 μM GEM at 24, 48 and 72 hrs. (D) The expression pattern of miR-214 was detected by qRT-PCR in BxCP-3 cells treated with GEM. (E) The CCK-
8 assay was used to measure the inhibition effect of miR-214 on apoptosis of BxCP-3 cells induced by GEM. BxCP-3 cells were transfected with
H2O (MOCK), mimics-NC (NC), and miR-214 mimics (miR-214). Significant differences (* p < 0.05; ** p < 0.01) compared with the control were
calculated using Dunnett’s test or the paired Student’s t-test.
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the kinases ERK and Akt. Here, we demonstrated that
WNT3A may also be a direct target of miR-15a. More-
over, we identified FGF7, a fibroblast growth factor, as
another potential target of miR-15a. FGF7 was reported
to play an important role in pancreatic organogenesis,
and FGF10/FGFR2 signaling recently emerged as a pro-
mising new molecular target for pancreatic cancer [26].
MiR-15a directly targets multiple genes relevant in pan-
creatic cancer and therefore may serve as a novel thera-
peutic target in pancreatic cancer.
The tumor suppressor ING4 belongs to the ING
family of genes, which comprises type II tumor suppres-
sor genes [27,28] involved in cell cycle arrest, transcrip-
tional regulation, DNA repair and apoptosis.
Downregulation of ING4 has been reported in various
tumors, including gliomas, breast tumors and stomach
adenocarcinoma. Hepatocellular carcinoma (HCC)
patients with low ING4 expression had poorer overall
survival and disease-free survival than those with high
expression [29]. Xie et al. found that upregulation of
ING4 could suppress lung carcinoma cell invasiveness
Table 2 Target validation for miR-15a
miR-15a
target




PIM1 F TCGAGTACTTGAACTTGCCTCTTTTACCTGCTGCTTCTCCAAAAATCTGCCTGGGTTGC YES NT
R GGCCGCAACCCAGGCAGATTTTTGGAGAAGCAGCAGGTAAAAGAGGCAAGTTCAAGTAC
CDC25A F TCGAGGAGTAGAGAAGTTACACAGAAATGCTGCTGGCCAAATAGCAAAGACAACCTGGC YES NT
R GGCCGCCAGGTTGTCTTTGCTATTTGGCCAGCAGCATTTCTGTGTAACTTCTCTACTCC
BCL2L2 F TCGAGGATTTTATTTGCATTAAGGGGTTTGCTGCTGAAAAAAAGTTGGAAAACCACTGC YES NT
R GGCCGCAGTGGTTTTCCAACTTTTTTTCAGCAGCAAACCCCTTAATGCAAATAAAATCC
WNT3A F TCGAGCGTTTTTGGTTTTAATGTTATATCTGATGCTGCTATATCCACTGTCCAACGGGC YES YES
R GGCCGCCCGTTGGACAGTGGATATAGCAGCATCAGATATAACATTAAAACCAAAAACGC
SMAD7 F TCGAGCAGGCCACACTTCAAACTACTTTGCTGCTAATATTTTCCTCCTGAGTGCTTGGC YES NT
R GGCCGCCAAGCACTCAGGAGGAAAATATTAGCAGCAAAGTAGTTTGAAGTGTGGCCTGC
LRP6 F TCGAGTATATATTTTCTTAAAACAGCAGATTTGCTGCTTGTGCCATAAAAGTTTGTAGC YES NT
R GGCCGCTACAAACTTTTATGGCACAAGCAGCAAATCTGCTGTTTTAAGAAAATATATAC
FGF7 F TCGAGTATTCCTATCTGCTTATAAAATGGCTGCTATAATAATAATAATACAGATGTTGC YES YES
R GGCCGCAACATCTGTATTATTATTATTATAGCAGCCATTTTATAAGCAGATAGGAATAC
The 59-bp segments of the 3’-UTR of each target gene are listed in this table. F (forward sequence) and R (reverse sequence) were annealed together and
inserted into the psi-CHECK-control vector. NT, negative.
Table 3 Target validation for miR-214
miR-214
target




PIM1 F TCGAGTACTTGAACTTGCCTCTTTTACCTGCTGCTTCTCCAAAAATCTGCCTGGGTTGC YES NT
R GGCCGCAACCCAGGCAGATTTTTGGAGAAGCAGCAGGTAAAAGAGGCAAGTTCAAGTAC
RASSF5 F TCGAGCTCCCTTTAGAAACTCTCTCCCTGCTGTATATTAAAGGGAGCAGGTGGAGAGC YES NT
R GGCCGCTCTCCACCTGCTCCCTTTAATATACAGCAGGGAGAGAGTTTCTAAAGGGAGC
BAX F TCGAGTGATCAATCCCCGATTCATCTACCCTGCTGACCTCCCAGTGACCCCTGACCTGC YES NT
R GGCCGCAGGTCAGGGGTCACTGGGAGGTCAGCAGGGTAGATGAATCGGGGATTGATCAC
BIK F TCGAGACCACTGCCCTGGAGGTGGCGGCCTGCTGCTGTTATCTTTTTAACTGTTTTCGC YES NT
R GGCCGCGAAAACAGTTAAAAAGATAACAGCAGCAGGCCGCCACCTCCAGGGCAGTGGTC
NEO1 F TCGAGTGTGTCGAGGCAGCTTCCCTTTGCCTGCTGATATTCTGCAGGACTGGGCACCGC YES NT
R GGCCGCGGTGCCCAGTCCTGCAGAATATCAGCAGGCAAAGGGAAGCTGCCTCGACACAC
ING4 F TCGAGGTAAATAAAAGCTATACATGTTGGCCTGCTGTGTTTATTGTAGAGACACTGTGC YES YES
R GGCCGCACAGTGTCTCTACAATAAACACAGCAGGCCAACATGTATAGCTTTTATTTACC
ACVR1B F TCGAGTCATTGGGGGGACCGTCTTTACCCCTGCTGACCTCCCACCTATCCGCCCTGCGC YES NT
R GGCCGCGCAGGGCGGATAGGTGGGAGGTCAGCAGGGGTAAAGACGGTCCCCCCAATGAC
The 59-bp segments of the 3’-UTR of the target genes are listed in the table. F (forward sequence) and R (reverse sequence) were annealed together and
inserted into the psi-CHECK-control vector. NT, negative.
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also reported that miR-650 targets ING4 to promote
g a s t r i cc a n c e rt u m o r i g e n i c i t y[ 3 1 ] .I nt h ep r e s e n ts t u d y ,
we found that ING4 is a potential target of miR-214,
which was overexpressed in pancreatic cancer and could
modulate the sensitivity to GEM-induced apoptosis in
BxCP-3 cells. Expression levels of miR-214 could poten-
tially serve as prognostic markers; however, the utility of
miR-214 as a therapeutic target in human pancreatic
cancer remains to be determined.
Conclusions
MiR-15a and miR-214 were found to be aberrantly
expressed in human pancreatic cancer and to play dif-
ferent roles in the development of the disease. Overex-
pression of exogenous miR-15a inhibited the viability of
pancreatic cancer cells, suggesting that downregulation
of miR-15a might be involved in the progression of pan-
creatic cancer. Moreover, we confirmed that WNT3A
and FGF7 are potential targets of miR-15a. MiR-15a
directly targets multiple genes relevant in pancreatic
Figure 3 Target validation of miR-15a and miR-214. (A) The 3’-UTR of WNT3A and FGF7 contain predicted MREs for miR-15a. (B) The 3’-UTR
of ING4 contains the predicted MRE for miR-214. (C) A luciferase assay was used to measure the activity of the 3’-UTR reporter in 293T cells.
MiR-15a inhibited the activity of WNT3A and FGF7 3’-UTR reporters, whereas miR-214 inhibited the activity of the ING4 3’-UTR reporter.
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tic target in pancreatic cancer. MiR-214 is another
miRNA that is dysregulated in pancreatic cancer. We
found that miR-214 promoted survival of pancreatic
cancer cells as well as GEM resistance, which might be
related to the poor response to chemotherapy in pan-
creatic cancer patients. We also identified ING4 as a
potential target of miR-214. The detailed mechanisms
and signaling pathways regulated by miR-15a and miR-
214 in pancreatic cancer deserve further study.
Materials and methods
Cell cultures and clinical samples
BxPC-3 human pancreatic cancer cells were maintained
in RPMI 1640 medium containing 10% fetal bovine
serum (FBS; Gibco BRL). 293T cells were maintained in
DMEM containing 10% FBS.
Ten samples of pancreatic cancer tissues and their
adjacent benign tissues were obtained from patients at
the Second Affiliated Hospital of Sun Yat-sen University.
All specimens were immediately snap-frozen in liquid
nitrogen and stored at -80°C. Patient characteristics are
available for all patients. Written informed consent for
the biological studies was obtained from the patients
involved in the study or from their parents/guardians.
The study was approved by the Ethics Committee of the
affiliated hospitals of Sun Yat-sen University.
RNA extraction and qRT-PCR
Total RNA was isolated with Trizol (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions. qRT-
PCR was performed as previously described [32] using
the Hairpin-it™miRNAs Real-Time PCR Quantization Kit
(GenePharma, Shanghai, China) containing a stem-
loop-like RT primer and PCR primers specific to the var-
ious miRNAs or the U6 RNA internal control (Table 4).
The expression of miRNAs in tumor tissues relative to
that in adjacent benign tissues was determined using the
2
-ΔΔCT method [33]. Briefly, the △CT of each miRNA was
determined relative to that of the U6 endogenous control
RNA, which was robustly and invariantly expressed
across all samples. MiRNA expression levels in each of
the 10 microdissected pancreatic cancer tissues were
compared against matched benign pancreatic tissues, and
each sample was assessed in triplicate for each miRNA.
Target gene prediction
Target gene prediction was performed to meet the fol-
lowing two criteria. First, miRNA targets were analyzed
using following algorithms, TARGETSCAN http://www.
targetscan.org/, PICTAR http://pictar.mdc-berlin.de/,
TargetBoost, and Miranda (Miranda IM - Home of the
Miranda IM client. Smaller, Faster, Easier) and miRBase
http://microrna.sanger.ac.uk/sequences/index.shtml. Sec-
ond, to reduce the likelihood of false positives, only
Table 4 qRT-PCR Primers for miRNAs and U6
miRNA Primer name Primer sequence (5’ to 3’)
miR-15a RT-primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAC CACAAAC
QF GCGGCTAGCAGCACATAATGG
miR-27a RT-primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAC GCGGAAC
QF GCGGCTTCACAGTGGCTAAGT




miR-181 RT-primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAC ACTCACC
QF GCGGCAACATTCAACGCTGTC
miR-200a RT-primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAC ACATCGT
QF GCGGCTAACACTGTCTGGTAA





All primers are listed in this table. The RT-primer was used for the reverse transcriptase reaction. QF and QR were used for the PCR reaction. QR was
applied to each miRNA test. U6QF and U6QR were used for examination of the U6 gene.
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programs were accepted.
Cell proliferation and apoptosis assay
BxPC-3 cells (1 × 10
4 per well) were plated in 96-well
plates in RPMI medium 1640 and 10% FBS that was
supplemented with sodium pyruvate at 37°C in a humi-
dified atmosphere of 5% CO2. Cells were transfected
with 100 nM miRNA duplex (Ambion) or scrambled
duplex (negative control, Ambion) using Lipofectamine
2000 (Invitrogen). For the cell viability study, cytotoxi-
city was determined in BxCP-3 cells treated with GEM
using the CCK-8 assay. Cells were plated at 1 × 10
4 per
well in a 96-well plate and allowed to adhere for 8 hrs.
The cells were then cultured in the absence or presence
of 10 μM GEM for 24, 48 or 72 hrs. After GEM treat-
ment, cell viability was measured using the CCK-8 assay.
Data analysis
Statistical analysis was performed using one-way analysis
of variance (ANOVA Dunnett’s test) for multiple sam-
ples. The paired Student’s t-test was used to analyze the
difference between the control and miRNA-transfected
cells. All p-values were obtained using SPSS software,
and p-values of <0.05 were considered to be statistically
significant.
Fluorescence reporter construction and luciferase assay
The 3’-untranslated terminal region (3’-UTR) segments
( T a b l e2 ,T a b l e3 )o f5 9b po ft h e3 ’-UTR of the target
genes were synthesized by Sangon (Shanghai) and
inserted into the psi-CHECK-control vector (Promega)
for miRNA functional analysis.
Transient transfection was performed in 293T cells
with 100 nM miR-15a or miR-214 mimics and 0.1 μgo f
psi-CHECK-control or psi-CHECK-3’UTR fluorescence
reporter constructs. Fluorescent activities were measured
consecutively using Dual-Luciferase assays (Promega) 24
hrs after transfection, according to the instructions of
the manufacturer.
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